3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Urinary Bladder Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Medulloblastoma
1
Lung Neoplasms
1
Leukemia, Hairy Cell
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Ependymoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma in Situ
1
Breast Neoplasms
1
Interventions
pembrolizumab
119
Cisplatin
33
lenvatinib
29
Carboplatin
28
Paclitaxel
27
Docetaxel
14
Pemetrexed
13
Fluorouracil
12
Capecitabine
11
Saline Solution
10
Oxaliplatin
10
Gemcitabine
10
Albumin-Bound Paclitaxel
7
olaparib
6
Leucovorin
6
Bevacizumab
6
epacadostat
5
belzutifan
5
Etoposide
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enzalutamide
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Radiotherapy
3
Levoleucovorin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Histamine Antagonists
×
1 year
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled